PROCURITAS
24.8.2021 09:32:05 CEST | Business Wire | Press release
Procuritas Capital Investors V (“Procuritas”), the private equity investor focused on investing in and growing Nordic mid-market companies, today announced that it has sold Dantherm Group (“Dantherm”), the leading provider of climate control products and solutions, to German private equity fund, DBAG Fund VIII, advised by Deutsche Beteiligungs AG.
Headquartered in Denmark, Dantherm has more than 60 years’ experience in designing and manufacturing high quality and energy efficient equipment for heating, cooling, drying, cleaning and ventilation for a wide range of portable and installed applications.
After acquiring the business in 2016, Procuritas invested in Dantherm to enable it to expand the geographical presence, to expand the product range and to take a leading market position in its core businesses in Europe.
Alongside the expansion of the business’ sales capabilities, strengthened senior management team and investment in its own manufacturing capacity, Procuritas utilized its extensive value creation expertise and network to partner with the Group to implement an active buy and build strategy. Under Procuritas’ ownership, Dantherm acquired close to 20 entities in its core markets of the UK, Italy, Denmark, Germany, France, Poland, Russia, Switzerland and Spain, realizing considerable integration synergies and significantly expanding the group’s capabilities and scale, resulting in a more than threefold rise in revenues and EBITDA growth of almost 700%.
Dantherm now operates in Norway, Sweden, Denmark, United Kingdom, Germany, Switzerland, Italy, Spain, Poland, Russia, France and China, where its strong brands – Aerial, Aircenter, BioCool, Calorex, Dantherm, Heylo, Master, SET and Sovelor – have well-established market positions. The group’s customers benefit from a comprehensive knowledge base and the experience and expertise from more than three million climate control products and solutions sold worldwide.
Hans Wikse, Partner at Procuritas, commented: “We are delighted to have sold Dantherm to DBAG Fund VIII, advised by Deutsche Beteiligungs AG, having received keen interest from several parties. We think it is a great fit for the company and they will have a great future. Dantherm has been a classic buy and build investment for Procuritas and our strategy was implemented following the methodical process we have undertaken with many other investments over the years.”
Bjarke Brøns, CEO of Dantherm commented: “ Over the past six years we have transformed Dantherm to become a market leading provider of selected climate control solutions. Procuritas has been a great partner to work with and their expertise in transforming companies through acquisition and by institutionalizing the business has been a great support as we have grown the Group. We see continued and extended market opportunities within our business and are excited to continue the development of Dantherm in the future with DBAG.”
Oskar Lindholm-Wu, Partner at Procuritas, commented: “It has been a pleasure to work with the Dantherm team, putting our passion for building strong sustainable businesses through transformational growth to work. Together, we have achieved remarkable growth, transforming the group into the leader in all its core markets across Europe. We wish Dantherm a prosperous future.”
DC Advisory served as M&A advisor, Kromann Reumert as legal advisor and EY as financial due diligence advisor to Procuritas and Dantherm in connection with the transaction.
About Procuritas
Procuritas is a private equity investor, focused on investing in and growing Nordic mid-market companies. With a passion for business, hands-on active ownership approach and more than thirty-year record from a large variety of transactions, it has supported more than 45 companies in accelerating their growth and realizing their true business potential. As owners, Procuritas is characterized by its enthusiasm, commitment, and strong belief that it is an ally in the quest to build strong and sustainable businesses. Read more at www.procuritas.com .
About Dantherm Group
Headquartered in Skive, Denmark, the Dantherm Group is a European leader in portable and installed climate control solutions for a wide range of industries within heating, drying, cooling, cleaning and ventilation. Dantherm has subsidiaries in Norway, Sweden, UK, Germany, Switzerland, Italy, France, Spain, Poland, Russia and China. In 2016 the Dantherm Group was acquired by Procuritas Capital Investors V LP. Read more at www.danthermgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
